论文部分内容阅读
目的:探讨吉非替尼对肺癌患者血清血管内皮生长因子(VEGF)、细胞角蛋白(CYFRA21-1)、糖类抗原(CA125)、癌胚抗原(CEA)及基质金属蛋白酶(MMP-9)水平影响研究及临床疗效。方法:选取前来我院就诊的已确诊的晚期非小细胞肺癌患者68例,随机分为对照组和治疗组,每组34例。对照组给予多西紫杉醇治疗,治疗组采用吉非替尼治疗,比较治疗前后两组患者血清VEGF、CYFRA21-1、CA125、CEA及MMP-9水平的变化、临床疗效及3年生存率。结果:治疗组总有效率及3年后生存率均明显高于对照组(P<0.05);治疗后,两组患者血清VEGF、CYFRA21-1、CA125、CEA及MMP-9水平均较治疗前显著降低(P<0.05),治疗组患者血清VEGF、CYFRA21-1、CA125、CEA及MMP-9水平低于对照组(P<0.05)。结论:吉非替尼对晚期非小细胞肺癌患者的治疗效果良好,其机制可能与降低血清VEGF、CYFRA21-1及CA125、CEA、MMP-9水平有关。
Objective: To investigate the effect of gefitinib on the expression of serum vascular endothelial growth factor (VEGF), cytokeratin (CYFRA21-1), carbohydrate antigen (CA125), carcinoembryonic antigen (CEA) and matrix metalloproteinase (MMP-9) Horizontal Impact Study and Clinical Efficacy. Methods: Sixty-eight patients with diagnosed advanced non-small cell lung cancer who came to our hospital were selected and randomly divided into control group and treatment group with 34 cases in each group. The control group was treated with docetaxel. The treatment group was treated with gefitinib. The changes of serum VEGF, CYFRA21-1, CA125, CEA and MMP-9 levels, clinical efficacy and 3-year survival rate were compared between the two groups before and after treatment. Results: The total effective rate and the survival rate after 3 years in the treatment group were significantly higher than those in the control group (P <0.05). After treatment, the levels of VEGF, CYFRA21-1, CA125, CEA and MMP-9 in the two groups were significantly higher than those before treatment (P <0.05). The levels of serum VEGF, CYFRA21-1, CA125, CEA and MMP-9 in the treatment group were lower than those in the control group (P <0.05). Conclusion: Gefitinib treatment of advanced non-small cell lung cancer patients with good effect, and its mechanism may be related to the reduction of serum VEGF, CYFRA21-1 and CA125, CEA, MMP-9 levels.